<it>pncA</it> mutations in clinical <it>Mycobacterium tuberculosis</it> isolates from Korea
<p>Abstract</p> <p>Background</p> <p>Pyrazinamide (PZA) is among the first-line drugs for the treatment of tuberculosis. In vitro, it kills semidormant mycobacteria only at low pH. The purpose of this study was to compare PZA resistance with pyrazinamidase (PZase) activ...
Main Authors: | Kim Cheol Min, Son Han Chul, Lee Min Ki, Chang Chulhun Ludgerus, Lee Jung Yoo, Park Soon Kew, Jang Hyun Jung, Park Hee Kyung, Jeong Seok Hoon |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2001-06-01
|
Series: | BMC Infectious Diseases |
Online Access: | http://www.biomedcentral.com/1471-2334/1/4 |
Similar Items
-
Characterization of the mutation region of the Mycobacterium tuberculosis PncA protein
by: Wen-Chung Chen, et al.
Published: (2009) -
Pyrazinamide resistance and the pncA gene variability in mycobacterium tuberculosis and related bacteria
by: Bamaga, Mohammad Salih
Published: (2005) -
Novel Mutations in pncA Gene of Pyrazinamide Resistant Clinical Isolates of Mycobacterium tuberculosis
by: Manijeh Kahbazi, et al.
Published: (2018-04-01) -
Characteristics of <it>pncA </it>mutations in multidrug-resistant tuberculosis in Taiwan
by: Lee Yu-Chin, et al.
Published: (2011-09-01) -
Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan
by: Muhammad Tahir khan, et al.
Published: (2019-02-01)